Published in Growth Factors on January 01, 1993
Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis (2012) 4.42
Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer (1998) 3.93
Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc Natl Acad Sci U S A (1996) 2.77
Oxidative stress in the placenta. Histochem Cell Biol (2004) 2.16
Placenta growth factor augments endothelin-1 and endothelin-B receptor expression via hypoxia-inducible factor-1 alpha. Blood (2008) 2.09
Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. Am J Pathol (2001) 1.69
Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am J Pathol (1998) 1.61
The discovery of placenta growth factor and its biological activity. Exp Mol Med (2012) 1.43
PlGF: a multitasking cytokine with disease-restricted activity. Cold Spring Harb Perspect Med (2012) 1.32
Vascular tissues are a primary source of BMP2 expression during bone formation induced by distraction osteogenesis. Bone (2012) 1.25
Placenta growth factor expression is correlated with survival of patients with colorectal cancer. Gut (2005) 1.12
Involvement of miR-30c and miR-301a in immediate induction of plasminogen activator inhibitor-1 by placental growth factor in human pulmonary endothelial cells. Biochem J (2011) 1.09
The role of heterodimerization between VEGFR-1 and VEGFR-2 in the regulation of endothelial cell homeostasis. Nat Commun (2012) 1.04
Expression of Placenta growth factor (PlGF) in non-small cell lung cancer (NSCLC) and the clinical and prognostic significance. World J Surg Oncol (2005) 1.03
New insights into molecular mechanisms of diabetic kidney disease. Am J Kidney Dis (2014) 1.02
Placenta growth factor induces 5-lipoxygenase-activating protein to increase leukotriene formation in sickle cell disease. Blood (2008) 1.02
The relationship between transplacental O2 diffusion and placental expression of PlGF, VEGF and their receptors in a placental insufficiency model of fetal growth restriction. J Physiol (2003) 1.00
What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis? Am J Pathol (1998) 0.93
Tying the knot: the cystine signature and molecular-recognition processes of the vascular endothelial growth factor family of angiogenic cytokines. FEBS J (2011) 0.90
Synthesis and physiological activity of heterodimers comprising different splice forms of vascular endothelial growth factor and placenta growth factor. Biochem J (1996) 0.84
Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes. Angiogenesis (2016) 0.84
Intramyocardial sustained delivery of placental growth factor using nanoparticles as a vehicle for delivery in the rat infarct model. Int J Nanomedicine (2011) 0.83
Vascular endothelial growth factor and placenta growth factor in intrauterine growth-restricted fetuses and neonates. Mediators Inflamm (2005) 0.82
Flt-1 in colorectal cancer cells is required for the tumor invasive effect of placental growth factor through a p38-MMP9 pathway. J Biomed Sci (2013) 0.79
Proteolytic processing regulates placental growth factor activities. J Biol Chem (2013) 0.78
Maternal diabetes impairs oxidative and inflammatory response in murine placenta. Springerplus (2016) 0.75
Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature (1992) 10.10
Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood (1996) 5.31
VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol (1997) 2.43
Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer (1994) 2.24
Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst (1995) 2.07
Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene (1994) 2.01
Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res (1999) 2.00
Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1. J Biol Chem (1996) 1.81
Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids. Lab Invest (2000) 1.66
AIDS-associated Kaposi's sarcoma cells in culture express vascular endothelial growth factor. Biochem Biophys Res Commun (1992) 1.60
Cooperative effect of TNFalpha, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J Cell Biol (1996) 1.49
Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer. Br J Cancer (2005) 1.28
Platelet-derived growth factor-induced transcription of the vascular endothelial growth factor gene is mediated by protein kinase C. Cancer Res (1992) 1.24
Receptors of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in fetal and adult human kidney: localization and [125I]VEGF binding sites. J Am Soc Nephrol (1998) 1.22
Differential expression of the two VEGF receptors flt and KDR in placenta and vascular endothelial cells. J Cell Biochem (1994) 1.18
Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab (1995) 1.15
Differential binding characteristics and cellular inhibition by soluble VEGF receptors 1 and 2. Exp Cell Res (1998) 1.12
Vascular endothelial growth factor is a potent angiogenic factor in AIDS-associated Kaposi's sarcoma-derived spindle cells. J Immunol (1997) 1.08
The effects of growth factors on the day 13 chorioallantoic membrane (CAM): a study of VEGF165 and PDGF-BB. Anat Embryol (Berl) (1992) 1.07
Preparation of biologically active platelet-derived growth factor type BB from a fusion protein expressed in Escherichia coli. Biochemistry (1989) 1.03
In vivo effects of vascular endothelial growth factor on the chicken chorioallantoic membrane. Cell Tissue Res (1993) 1.02
Soluble VEGF receptors. Angiogenesis (1999) 1.01
Endothelial growth factor receptors in human fetal heart. Circulation (1999) 0.99
Expression and localization of placenta growth factor and PlGF receptors in human meningiomas. J Pathol (1999) 0.99
Involvement of VEGFR-2 (kdr/flk-1) but not VEGFR-1 (flt-1) in VEGF-A and VEGF-C-induced tube formation by human microvascular endothelial cells in fibrin matrices in vitro. Angiogenesis (2001) 0.98
Basic fibroblast growth factor modulates the mitogenic potency of the platelet-derived growth factor (PDGF) isoforms by specific upregulation of the PDGF alpha receptor in vascular smooth muscle cells. J Biol Chem (1992) 0.97
Detection and quantification of vascular endothelial growth factor/vascular permeability factor in brain tumor tissue and cyst fluid: the key to angiogenesis? Neurosurgery (1994) 0.92
Secretion of vascular endothelial growth factor/vascular permeability factor from human luteinized granulosa cells is human chorionic gonadotrophin dependent. Mol Hum Reprod (1998) 0.92
VEGF121 induces proliferation of vascular endothelial cells and expression of flk-1 without affecting lymphatic vessels of chorioallantoic membrane. Dev Biol (1996) 0.92
Characterization of (123)I-vascular endothelial growth factor-binding sites expressed on human tumour cells: possible implication for tumour scintigraphy. Int J Cancer (2001) 0.90
Lymphatics and inflammation. Curr Med Chem (2009) 0.90
Preparation of biologically active platelet-derived growth factor isoforms AA and AB. Preferential formation of AB heterodimers. Eur J Biochem (1990) 0.87
Effects of vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF) on haemodynamics and permselectivity of the isolated perfused rat kidney. Nephrol Dial Transplant (1998) 0.86
Synthesis and assembly of functionally active human vascular endothelial growth factor homodimers in insect cells. Eur J Biochem (1993) 0.86
Vascular endothelial growth factor (VEGF) messenger ribonucleic acid (mRNA) expression in luteinized human granulosa cells in vitro. J Clin Endocrinol Metab (1993) 0.86
Detection and quantification of complexed and free soluble human vascular endothelial growth factor receptor-1 (sVEGFR-1) by ELISA. J Immunol Methods (1999) 0.85
Expression of genes coding growth factors and growth factor receptors in differentiated and dedifferentiated human corneal endothelial cells. Cornea (1995) 0.85
Endothelial survival factors and spatial completion, but not pericyte coverage of retinal capillaries determine vessel plasticity. FASEB J (2005) 0.85
Synthesis and physiological activity of heterodimers comprising different splice forms of vascular endothelial growth factor and placenta growth factor. Biochem J (1996) 0.84
Perspectives in the biological function, the technical and therapeutic application of bone morphogenetic proteins. Appl Microbiol Biotechnol (2001) 0.83
The long 3'-untranslated regions of the PDGF-A and -B mRNAs are only distantly related. FEBS Lett (1987) 0.83
Distinct capillary density and progression promoted by vascular endothelial growth factor-A homodimers and heterodimers. Angiogenesis (1997) 0.82
Platelet-derived growth factor. Phorbol ester induces the expression of the B-chain but not of the A-chain in HEL cells. FEBS Lett (1987) 0.82
VEGF/Flk-1 interaction, a requirement for malignant ascites recurrence. J Interferon Cytokine Res (2000) 0.81
In vitro characterization of a slow release system of polylactic acid and rhBMP2. J Biomed Mater Res A (2007) 0.81
Ectopic bone formation after implantation of a slow release system of polylactic acid and rhBMP-2. Clin Oral Implants Res (2009) 0.79
The human osteosarcoma cell line U-2 OS expresses a 3.8 kilobase mRNA which codes for the sequence of the PDGF-B chain. FEBS Lett (1986) 0.78
Vascular endothelial growth factor and its relationships with endogenous inhibitors in a breast cancer microenvironment manipulated by hormonal therapy: a hypothetical consideration. Biomed Pharmacother (2005) 0.78
Developing renal microvasculature can be maintained under perfusion culture conditions. Eur J Cell Biol (1994) 0.77
Vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF) production by luteinized human granulosa cells in vitro; a paracrine signal in corpus luteum formation. Gynecol Endocrinol (1998) 0.76
[Effect of differentiation on expression of genes for growth factors and growth factor receptors in human corneal endothelial cells]. Ophthalmologe (1996) 0.75
Effects of vascular endothelial growth factor and basic fibroblast growth factor: application with corneal grafts on the chorioallantoic membrane. Acta Anat (Basel) (1993) 0.75